FDA supplemental approval: Buprenorphine (REMS)

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for buprenorphine transdermal film (7.5, 10, 15, and 20 mcg/hr) manufactured by Mylan Tech Viatris on 18 June 2026. This is a regulatory action addressing risk management, not a trial or efficacy assessment.

Plain-language summary

This is an FDA supplemental approval action updating the Risk Evaluation and Mitigation Strategy (REMS) for buprenorphine transdermal film products; it does not report clinical trial efficacy or safety data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This REMS supplement governs how buprenorphine transdermal film must be distributed and used to mitigate identified risks, but the record does not contain efficacy, safety trial data, or clinical guidance. Prescribers and dispensers should consult the approved REMS requirements for compliance.

Caveats

• This record does not contain clinical trial results, efficacy data, safety outcomes, or comparative effectiveness.
• The specific risk mitigation requirements are not detailed in this regulatory summary.
• No information on why the REMS was updated or what risks it addresses.
• Population and indication are not specified in this regulatory action record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.